Author

Yindan Lin

University of Kentucky

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Avery R. ChildressiD· 2 shared Christian M. GosseriD· 2 shared Christine F. BrainsoniD· 2 shared Daniel R. PlaugheriD· 2 shared Dave-Preston I. Esoe· 2 shared Jinpeng LiuiD· 2 shared Tanner J. DuCoteiD· 2 shared Alba Bundo· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Avery R. ChildressORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming

Avery R. Childress, Dave-Preston I. Esoe, Xiulong Song, Christian M. Gosser, Yindan Lin, Daniel R. Plaugher, Tanner J. DuCote, Kassandra J. Naughton, Erika M. Skaggs, Harrison Yang, Ryan A. Goettl, Jinpeng Liu, Zhonglin Hao, Albert Fliss, Daisuke Honma, , Christine F. Brainson

This study shows that EZH1/2 inhibition with valemetostat enhances anti-PD1 immunotherapy in lung squamous cell carcinoma by increasing MHC Class II and reprogramming neutrophils.

bioRxiv · Aug 1, 2026 · PreprintCancer Biology

Multispecific nanobody degraders co-deplete membrane receptors and enable targeted delivery of diverse payloads

Md Kabir, Yong Joon (Jeffrey) Kim, Zhijie Deng, Yufei Xiang, Paul R. Sargunas, Nuozi Song, Zishan Wang, Nesteene Joy Param, Changzhong Jin, Zhe Sang, Alicia Yue, Alba Bundo, Razeen Hossain, Yue Zhong, Yindan Lin, , Yi Shi

This paper develops MINDS, a multispecific nanobody-Fc platform that co-depletes membrane receptors and delivers diverse payloads, showing improved antitumor activity in cancer models.

bioRxiv · May 6, 2026 · PreprintCancer Biology

EZH2 Inhibition Boosts Tumor Immunogenicity and TIL Reactivity in Lung Cancer

Daniel R. Plaugher, Christian M. Gosser, Yindan Lin, Avery R. Childress, Jinpeng Liu, Jinze Liu, Xufeng Qu, Tanner J. DuCote, Dave-Preston I. Esoe, Siva K. Gandhapudi, Christine F. Brainson

This study shows that inhibiting EZH2 in lung cancer enhances immunogenicity and TIL reactivity by altering the tumor microenvironment and T cell properties.

bioRxiv · Jul 12, 2025 · PreprintSystems Biology